Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ATLG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematopoietic Stem Cell Transplantation
1 trial -
ATOMOXETINE , PAROXETINE , MIANSERIN , VORTIOXETINE , VENLAFAXINE , DESVENLAFAXINE , KETAMINE , CLOMIPRAMINE , DULOXETINE , DOSULEPIN , IMIPRAMINE , AMITRIPTYLINE , ESCITALOPRAM , NORTRIPTYLINE , MILNACIPRAN , SERTRALINE , ESKETAMINE , FLUVOXAMINE , REBOXETINE , FLUOXETINE , TRAZODONE , CITALOPRAM , BUPROPION , AGOMELATINE , MIRTAZAPINE , ESKETAMINE , TIANEPTINE
Disc Medicine
Major depressive disorder
1 trial -
ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN
Novartis Pharmaceuticals
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.
1 trial -
AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -
Sanofi-aventis Healthcare Pty Ltd
Nervous system diseases
1 trial -
AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab
Sanofi-aventis Healthcare Pty Ltd
multiple sclerosis
1 trial -
AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
AVP-786 matching Placebo, AVP-786, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AVP-786 matching placebo, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE
Lacuna Pharma Pty Ltd
Acute myeloid leukemia
1 trial -
AZACITIDINE, Venetoclax, Venetoclax, Venetoclax
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukaemia
1 trial -
AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f
AstraZeneca AB
Relapsed or Refractory Multiple Myeloma
1 trial -
AZD0780
AstraZeneca
Cardiovascular Disease
1 trial -
AZD0780
AstraZeneca
Heterozygous Familial Hypercholesterolaemia
1 trial -
AZD0780 Placebo, AZD0780
AstraZeneca AB
Heterozygous familial hypercholesterolaemia
1 trial -
AZD0780, AZD0780 Placebo
AstraZeneca AB
Hyperlipidemia, Atherosclerotic cardiovascular disease
1 trial -
AZD0780, AZD0780 placebo
AstraZeneca AB
Atherosclerotic Cardiovascular Disease
1 trial -
AZD7270, AZD7270, Lokelma 5 g powder for oral suspension, AZD7270, Lokelma 5 g powder for oral suspension
AstraZeneca AB
Hyperkalaemia
1 trial -
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Gilead Sciences Ireland UC
Cystic Fibrosis
1 trial -
Abemaciclib, Lasofoxifene, Fulvestrant
Lacuna Pharma Pty Ltd
Locally advanced or metastatic breast cancer
1 trial -
Abicipar Pegol
Allergan Pharmaceuticals International Limited
Macular Degeneration
1 trial -
Abiraterone - Usual
Lxo Ireland Designated Activity Company
Prostate Cancer
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN , PEMBROLIZUMAB, CARBOPLATIN , PACLITAXEL , PEMETREXED
Fondazione Telethon ETS
metastatic NSCLC patients
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Ipsen
Metastatic Pancreatic Adenocarcinoma
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion
Gilead Sciences Pty Limited
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources